Over the past year there were no insider purchases at 10x Genomics, Inc.. Six insiders sold roughly $16.9 million instead.
Keep in mind most insider selling is routine — stock-based pay has to be converted to cash at some point.
Quarter by quarter: 6 quarters in a row of net selling by insiders. Insiders bought in 1 of the last 7 full quarters. Big money check: 390 institutions held TXG as of Q2 2026, and funds were split between buying and selling.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 24, 2026 | SULIMAN SHEHNAAZ | Director | Sell | 1,325 | $80.82 | $107K | SEC |
| Sep 24, 2026 | SULIMAN SHEHNAAZ | Director | Sell | 2,270 | $81.67 | $185K | SEC |
| Sep 24, 2026 | SULIMAN SHEHNAAZ | Director | Sell | 292 | $78.20 | $23K | SEC |
| Sep 24, 2026 | SULIMAN SHEHNAAZ | Director | Sell | 614 | $79.51 | $49K | SEC |
| Sep 24, 2026 | SULIMAN SHEHNAAZ | Director | Sell | 1,222 | $82.28 | $101K | SEC |
| Sep 24, 2026 | Saxonov Serge | CEO | Sell | 1,000 | $78.23 | $78K | SEC |
| Sep 24, 2026 | Saxonov Serge | CEO | Sell | 9,900 | $81.83 | $810K | SEC |
| Sep 24, 2026 | Saxonov Serge | CEO | Sell | 9,300 | $80.90 | $752K | SEC |
| Sep 24, 2026 | Saxonov Serge | CEO | Sell | 2,000 | $79.62 | $159K | SEC |
| Sep 24, 2026 | Saxonov Serge | CEO | Sell | 2,800 | $82.37 | $231K | SEC |
| Sep 11, 2026 | Taich Adam | CFO | Sell | 1,206 | $63.68 | $77K | SEC |
| Sep 11, 2026 | Taich Adam | CFO | Sell | 13,754 | $65.26 | $898K | SEC |
| Sep 11, 2026 | Taich Adam | CFO | Sell | 31,428 | $64.31 | $2.0M | SEC |
| Sep 8, 2026 | STUELPNAGEL JOHN R | Director | Sell | 6,814 | $62.11 | $423K | SEC |
| Sep 8, 2026 | STUELPNAGEL JOHN R | Director | Sell | 7,012 | $60.66 | $425K | SEC |
In the last 12 months 10x Genomics, Inc. insiders made open-market purchases worth about $0 and sales worth about $16.9 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in TXG was filed on 2026-09-24.
390 investment managers reported holding TXG in SEC Form 13F filings for Q2 2026.
No congressional trades in TXG were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).